Show the Working

Implement Infected Blood Inquiry Recommendations

Liberal Democrat · what the evidence says

An independent, source-checked look at Liberal Democrat’s policy “Implement Infected Blood Inquiry Recommendations” — what it would actually do across the things that affect your life. Every claim below quotes the source behind it. How this works.

Public finances & the next generation — Hurts

moderate · moderate confidence

Delivering full compensation to infected blood victims costs around £12.8 billion in public spending, worsening the near-term debt path. How much this harms long-run sustainability depends on whether the commitment is fully funded through tax or cuts elsewhere, which remains uncertain.

The evidence

Biggest unknown: Whether the £11.8–12.8bn provision is genuinely offset elsewhere in the public finances, or adds to net borrowing — and whether final claimant numbers push costs above current NAO estimates.

Our reading: The policy commits to implementing the Infected Blood Inquiry recommendations in full, including full compensation to all victims. This translates into a spending commitment of approximately £12.8bn (NAO, April 2026), provisioned at £11.8bn in the Autumn Budget 2024. This is a substantial, near-term charge on public finances. The key O12 question is whether this spending is funded or borrowed. The evidence notes that the compensation was at one point described as 'completely unfunded,' and while it has since been budgeted, the underlying liability still increases the debt path unless offset by cuts or revenue elsewhere — something this policy does not specify. The wide uncertainty in claimant numbers (infected: 8,500–16,500; affected: ~51,000) means the final bill could exceed the £12.8bn NAO estimate, potentially approaching the upper bound of earlier estimates exceeding £20bn. This fiscal risk is real. On the long-run dimension, unlike productive investment, compensation payments are transfers — they do not raise future productive capacity and therefore do not improve long-run debt sustainability in the way that, say, infrastructure borrowing might. There is no plausible mechanism by which this spending improves the debt path. The counterfactual is not 'zero liability' — the moral and legal obligation exists regardless — but as a policy of implementing in full (rather than phasing or capping), it locks in the full fiscal cost. The verdict is 'worsens' at moderate magnitude: the spending is large relative to fiscal headroom, largely consumption-oriented (transfers), and carries upside cost risk. Confidence is moderate because the budgetary treatment (funded vs. borrowed) is not fully resolved by the provided evidence.

Cost of living — Helps

moderate · moderate confidence

This policy delivers substantial financial compensation to tens of thousands of victims of the infected blood scandal, which directly improves their ability to afford essentials. However, payments are still rolling out, there are concerns about timeliness and fairness, and the benefit is confined to a specific group rather than the general population.

The evidence

Biggest unknown: Whether all eligible claimants receive payments in a genuinely timely manner, given ongoing concerns about delays and scheme design, will determine how much real-world cost-of-living relief is actually delivered.

Our reading: The infected blood scandal left tens of thousands of people — many of whom suffered serious, lifelong illness — without compensation for decades. Implementing the inquiry's recommendations, including full financial compensation, directly improves the cost-of-living position of this specific cohort. Awards cover financial loss, care costs, and loss of career progression, and interim payments of up to £210,000 have already been made to living victims. Over £2 billion has been paid out to more than 3,000 people, with a total scheme expected to reach £12.8 billion. These are material sums that can meaningfully improve recipients' ability to afford essentials, particularly given that many victims face ongoing health costs and lost earnings. The effect is 'moderate' rather than 'major' because it is concentrated on a specific, relatively small population (not the general public) and because ongoing concerns about timeliness and adequacy — including the Inquiry Chair's own intervention over 'unfair elements' — mean not all eligible people have yet received full relief. The counterfactual is clear: absent the policy, these individuals would remain uncompensated or only partially compensated, as the scandal had gone unaddressed for decades. The policy has a defined mechanism (IBCA, statutory scheme, government funding) that is already operational, so this is not merely aspirational. Confidence is moderate rather than high because the pace and completeness of payments remains uncertain, and the number of eligible claimants is itself uncertain (government estimates range from 8,500 to 51,000 depending on category).

Equal treatment & democratic rights — Helps

moderate · moderate confidence

This policy commits to implementing the Infected Blood Inquiry recommendations in full, including fair compensation for over 30,000 people who were harmed through NHS-administered contaminated blood — a major historic failure of due process and state accountability. Progress is real but victim groups have raised ongoing concerns about fairness and delays in the scheme's rollout.

The evidence

Biggest unknown: Whether the compensation scheme will reach all eligible claimants fairly and in a timely way, given the Inquiry Chair's own criticism of 'unfair elements' and the uncertainty in the number of eligible claimants (government estimates range from 8,500 to 16,500 infected people, with up to 51,000 affected people potentially eligible).

Our reading: The infected blood scandal represents one of the gravest historic failures of due process and equal treatment by a state institution in modern UK history: over 30,000 people were harmed through NHS-administered products, with more than 3,000 deaths. For decades, victims lacked accountability, recognition, or redress — a direct failure on O9's indicators of due process, rule of law, and equal treatment. Implementing the Inquiry's recommendations in full is therefore directly and substantially relevant to O9. The mechanism is not merely aspirational: a compensation scheme is operational, over £2 billion has been paid out to more than 3,000 claimants by March 2026, and the government has accepted the recommendations in full or in principle. These are delivered instruments, not soft commitments. Absent this policy, victims would remain without formal redress or acknowledgment — the counterfactual is clearly worse on O9. However, the direction is not straightforwardly 'major'. The Inquiry Chair himself intervened over 'unfair elements' in the scheme's initial design, and victim groups have criticised the process as lacking transparency and victim involvement. There remains genuine uncertainty about whether the full eligible population will be reached, given wide-ranging estimates of eligible claimants. These are real delivery deficits that temper the magnitude: the mechanism exists and is delivering, but it is not yet fully meeting its own stated standard of being 'timely and transparent' for all victims. The verdict is therefore 'improves/moderate' — material real-world progress on due process and accountability for a large group of citizens, with legitimate outstanding concerns about completeness and fairness of delivery.

Compare all parties on public finances & the next generation →Compare all parties on cost of living →Compare all parties on equal treatment & democratic rights →Open this in the interactive comparison →← Show the Working home